MobiHealth News January 22, 2021
Asset Management Ventures’ Skip Fleshman outlines COVID-19’s impact on clinical trials and the resulting leap toward tech-enabled decentralized trials.
Clinical trials have become big news this year amid the search for COVID-19 vaccines and treatments. They are a critical component of helping the FDA validate that new drugs and diagnostics will be both safe and effective.
Pharmaceutical companies spend over $45B a year running clinical trials, which are, by design, very methodical and measured. Unfortunately, they are also slow, unpredictable and massively inefficient. Some estimates indicate that every day a phase 3 clinical trial slips costs the pharma company as much as $8M.
There are a lot of problems: Recruitment is often difficult, and the cost to find patients is...
Today's Sponsors
Today's Sponsor